J. Scott Wolchko

2021

In 2021, J. Scott Wolchko earned a total compensation of $11.7M as President, Chief Executive Officer and Director at Fate Therapeutics, a 109% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$366,000
Option Awards$1,200,000
Salary$610,000
Stock Awards$9,552,617
Total$11,728,617

Wolchko received $9.6M in stock awards, accounting for 81% of the total pay in 2021.

Wolchko also received $366K in non-equity incentive plan, $1.2M in option awards and $610K in salary.

Rankings

In 2021, J. Scott Wolchko's compensation ranked 804th out of 12,405 executives tracked by ExecPay. In other words, Wolchko earned more than 93.5% of executives.

ClassificationRankingPercentile
All
804
out of 12,405
94th
Division
Manufacturing
263
out of 5,494
95th
Major group
Chemicals And Allied Products
86
out of 2,369
96th
Industry group
Drugs
73
out of 2,090
97th
Industry
Biological Products, Except Diagnostic Substances
24
out of 452
95th
Source: SEC filing on April 25, 2022.

Wolchko's colleagues

We found five more compensation records of executives who worked with J. Scott Wolchko at Fate Therapeutics in 2021.

2021

Mark Plavsic

Fate Therapeutics

Chief Technology Officer

2021

Bahram Valamehr

Fate Therapeutics

Chief Research and Development Officer

2021

Cindy Tahl

Fate Therapeutics

General Counsel

2021

Yu-Waye Chu

Fate Therapeutics

Chief Medical Officer

2021

Edward Dulac

Fate Therapeutics

Chief Financial Officer

News

You may also like